GE医疗中国CEO：未来三年在中国的研发投入将再翻一番

4月26日，GE医疗中国总裁兼首席执行官张轶昊在接受澎湃新闻等媒体采访时表示，当前GE医疗在中国的研发团队超过1800人，已经研发并投入市场近110款创新产品，将持续提高核心零件等的国产比例。目前GE医疗在中国销售设备的国产化率已超过70%，正在推动全系列、全链条的全面国产，未来三年在中国的研发投入将再翻一番。

2月24日，国药器械与GE医疗中国在中国成立首个由中方（国资）控股的医学影像设备合资企业。有分析认为这将开启跨国医疗企业本土化内卷升级，对此张轶昊回应道，有竞争是个好事，竞争之后得益的是老百姓。他指出，当前在中国的所有企业面临的最大挑战是能否提升自身核心竞争力去服务中国市场，中国用户可以用选择来投票。

如需加入CXO UNION（CXO联盟）高管社群，请联系社群小伙伴哦~

本文由CXO UNION-CXO联盟（cxounion.cn）转载而成，来源:知乎；作者：synge​；编辑：CXO UNIONCXO联盟小C。
免责声明: 本网站(http://www.cxounion.cn/)内容主要来自原创、合作媒体供稿和第三方投稿，凡在本网站出现的信息，均仅供参考。本网站将尽力确保所提供信息的准确性及可靠性，但不保证有关资料的准确性及可靠性，读者在使用前请进一步核实，并对任何自主决定的行为负责。本网站对有关资料所引致的错误、不确或遗漏，概不负任何法律责任。

翻译

On April 26, Zhang Yihao, president and CEO of GE Healthcare China. He said in an interview with ThePaper.cn that GE Healthcare has a research and development team of more than 1,800 people in China. It has developed and put nearly 110 innovative products into the market, and will continue to increase the proportion of domestic core parts. At present, the localization rate of GE Medical’s sales equipment in China has exceeded 70%, and it is promoting the full series and chain of domestic production. In the next three years, the R&D investment in China will double again.

On February 24, Sinopmedica and GE Healthcare established the first Chinese-controlled joint venture for medical imaging equipment in China. In response to the analysis. That this will open the door to the upgrading of multinational medical companies’ localization. Zhang Yihao said that competition is a good thing, and the people benefit from competition. He pointed out that the biggest challenge facing all enterprises in China is whether they can improve their core competitiveness to serve the Chinese market, and Chinese users can vote with their choices.